Indian pharma firm Zydus Cadila (NSE: CADILAHC) has been granted approval from the US Food and Drug Administration (FDA) to market Clobetasol Propionate ointment USP, 0.05%, in the US market, the company said on Monday.
Clobetasol Propionate ointment is used in the treatment of a range of skin conditions, such as eczema, dermatitis, allergies and rashes.
The company confirmed that the ointment will be manufactured at its Ahmedabad-based facility.
It marks the latest in the Zydus group's extensive portfolio of more than 165 product approvals.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children